Be a part of our medical cannabis research study!

GI Issues

Key Research Findings

Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. (2013)
  • “CBG was effective when given both before and after the inflammatory insult, suggesting a preventive and a curative (therapeutic) beneficial effect. Significant protective effects were achieved starting from the 1 mg/kg dose (preventive protocol) and 5 mg/kg (curative protocol).”
  • “Also, CBG exerts antioxidant effects in the inflamed gut as well as in intestinal epithelial cells exposed to oxidative stress. On the whole, these results could provide a pharmacological basis to explain, at least in part, the beneficial effects of Cannabis preparations observed in IBD patients using Cannabis.”
The endogenous cannabinoid system protects against colonic inflammation. (2004)
  • “In conclusion, this study shows that the endogenous cannabinoid system is physiologically involved in the protection against excessive inflammation in the colon, both by dampening smooth muscular irritation caused by inflammation and by controlling cellular pathways leading to inflammatory responses.”
  • “These results strongly suggest that modulation of the physiological activity of the endogenous cannabinoid system during colonic inflammation might be a promising therapeutic tool for the treatment of several diseases characterized by inflammation of the gastrointestinal tract.”
Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. (2012)
  • “Cannabinoids can affect both the activity and the expression of TRPV1-4 channels, with various potential therapeutic applications, including in the gastrointestinal tract.”
Gut feelings about the endocannabinoid system. (2011)
  • “…together with related studies published in other journals over the last 2 years, confirm that the ECS [endocannabinoid system] and related emerging signaling systems may play a fundamental role in the control of all aspects of GI physiology and pathology.”
The effects of Δ9‐tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis. (2010)
  • “It is well known that cannabis possesses immunosuppressive properties and that the main component responsible for this profile of action is THC…. In support of this, THC was effective in attenuating autoimmune responses in an experimental model of diabetes (multiple low-dose streptozotocin injections) and in experimental autoimmune encephalomyelitis.”
  • “Importantly, CBD has been also demonstrated to possess potent anti-inflammatory and immunomodulatory properties which, together with a lack of psychotropic activity and low toxicity, make it a very promising therapeutic candidate for a variety of inflammatory and pain associated disorders, including IBD. CBD is a very potent antioxidant, which results in reduction of the level of reactive oxygen species in the course of inflammation and protection from tissue damage.”
  • “Our results demonstrated that treatment with THC and CBD reduced inflammation and motility disturbances associated with colitis. The effects of THC alone and in combination with CBD were similar to and, in some aspects, better than those of sulphasalazine, suggesting potential value of phytocannabinoids for the treatment of IBD.”
Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis. (2009)
  • “In conclusion, our results show that the degree of intestinal inflammation caused by intracolonic administration of DNBS is substantially reduced by treatment of mice with the Cannabis-derived ingredient CBD.”
Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis.
  • “…these results suggest, for the first time, that CBD, by modulating the glial-immune axis, regulates the fire up of the inflammatory reaction in the intestine thereby preventing the detrimental intestinal damage.”
  • “…in this study we demonstrate that during intestinal inflammation, CBD is able to control the inflammatory scenario and the subsequent intestinal apoptosis through the restoration of the altered glia-immune homeostasis. CBD is therefore regarded as a promising therapeutic agent that modulates the neuroimmune axis, which can be recognised as a new target in the treatment of inflammatory bowel disorders.”